• Technology

Technology: T-win®

IO Biotech has a unique and novel technology platform, T-win, for developing immune modulating anti-cancer therapies

The discovery of naturally occurring, proinflammatory T-cells specific for immune inhibitory molecules (e.g., IDO and PD-L1) – termed ‘anti-regulatory T-cells’ - laid the basis for the IO Biotech approach. We aim to target and activate these self-reactive T-cells that can specifically remove the unwanted cells in the tumor microenvironment.

IO Biotech’s immune modulating anti-cancer therapies have a multifaceted mode of actions: they activate the patients’ own cytotoxic T-cells towards immune suppressive cells or cancer cells presenting the target peptide, hence the anti-cancer therapies act in two ways:

  1. Direct anti-cancer effect by killing of target expressing tumor cells

  2. Elimination of immune-suppressive cells, thereby augmenting the effector responses of surrounding T-cells in treated cancer patients

In addition, immune modulating anti-cancer therapies have the potential to induce long-term immunity.

Illustration of T-win technology platform

 

Publications by founders

The T-win® technology: immune-modulating vaccines
Seminars in Immunopathology, July 2018